 Mumbai:
The seventh Pharmaceuticals Analysts Convention, organised
jointly by Indian Drug Manufacturers Association (IDMA)
(www.idmaindia.com)
and Indian Pharmaceutical Association (IPA), brought
to light the various opportunities existing in the $102-billion
European pharmaceutical industry.
The
convention, which took place on 19 and 20 September,
facilitated a better understanding of the International
Conference on Harmonisation (ICH) guidelines, which
will lead to its compliance within the industry. This
will make it easier to obtain European approvals and
enter the European market. Compliance with ICH guidelines
will hold Indian companies on par with their global
counterparts.
The
convention was presided by eminent international speakers.
They included:
-
Dr
Agnes Artiges, director, European Pharmacopoeia Commission
-
Peter
Castle, secretary, European Pharmacopoeia Commission
-
Corinne
Pouget, principal scientific officer, head of certification
unit, EDQM, Council of Europe
-
Dr
Sultan Ghani, director, Bureau of Pharmaceutical Sciences
Therapeutic Products Directorate, Health Canada.
Says
IDMA general secretary Dara Patel: "The European
market, which is predicted to be valued at $108.3 billion
by 2007, holds immense prospects for the domestic Indian
pharma industry especially in the product patent era.
With low investment capacity in the ''discovery research''
sector the domestic Indian pharma industry can explore
areas like contract manufacturing and process research
and development in the European market."
The
convention also discussed in detail the intricate issues
involved in understanding the requirements for registration
of medicines in the European Union. It also acquainted
the participants with the intricacies of the European
pharmacopoeia as well as the Indian pharmacopoeia.
|
